Beta-Glucans

Compound Class	Beta-glucans — polysaccharides of D-glucose linked by β-glycosidic bonds, principally 1,3/1,6-linked (fungal) or 1,3/1,4-linked (cereal)
Representative Members	Fungal β-1,3/1,6-glucan (maitake, reishi, shiitake), cereal β-1,3/1,4-glucan (oat, barley)
Botanical Sources	Grifola frondosa (maitake), Ganoderma lucidum (reishi), Avena sativa (oat)
Plant Part(s)	Fruiting body (mushrooms), whole grain/bran (oat)
Typical Standardisation	Total β-glucan by enzymatic-gravimetric (Megazyme) assay; 20–30% common for mushroom extracts, higher for purified oat β-glucan concentrates
Primary Applications	Immune modulation, cholesterol management (cereal β-glucan, EFSA-recognised), postprandial glycaemic support
Claim Strength (Overview)	High for oat β-glucan cholesterol reduction (regulatory-recognised); Moderate for fungal β-glucan immune modulation
Buy from Herbuno	Beta-Glucans 30% Powder (Maitake Extract) | Standardized Grifola frondosa → Ganoderma Lucidum Reishi Extract Powder →

Name origin: Beta-glucan is a direct structural descriptor: a glucan (polymer of glucose) joined by beta-configuration glycosidic bonds, distinguishing it from the alpha-linked glucans that make up digestible starches — a single stereochemical difference in bond geometry that renders beta-glucans largely indigestible by human enzymes and therefore functionally and physiologically distinct from starch despite an identical glucose building block. Traditional use: The mushrooms richest in fungal beta-glucan — maitake ("dancing mushroom" in Japanese, reputedly named for the joy foragers expressed on finding it) and reishi ("spirit plant" in Chinese, lingzhi) — occupy some of the most prestigious positions in East Asian traditional medicine, with reishi documented in Chinese materia medica for over two thousand years as a longevity and vitality tonic, and maitake used both as a prized culinary mushroom and a folk remedy; oat, by contrast, entered the beta-glucan story through a purely nutritional rather than medicinal tradition, as a European and North American dietary staple. Research trajectory: Fungal beta-glucan research accelerated through Japanese oncology-adjacent research from the 1960s onward (lentinan, a related mushroom-derived beta-glucan, was developed as an approved adjuvant cancer therapy in Japan), while oat beta-glucan research followed a distinct, cardiometabolic-focused trajectory that culminated in formal regulatory health-claim recognition in both the United States and European Union. Commercial source: Maitake and reishi fruiting-body extracts are the dominant commercial fungal beta-glucan sources for immune-support positioning, while oat remains the dominant source for cholesterol-management positioning given its unique regulatory-claim status.

---

Evidence for Beta-Glucans Applications

Cereal beta-glucan carries the strongest regulatory recognition of any compound in this monograph series: following review of 22 references including three meta-analyses and 19 randomized controlled trials, the European Food Safety Authority concluded that a cause-and-effect relationship has been established between consumption of oat beta-glucan and lowering of blood LDL cholesterol, authorizing the claim wording "Oat beta-glucan has been shown to lower/reduce blood cholesterol" for products providing at least 3 g/day (EFSA 2010). This is among the small number of botanical/food-derived compounds in the HerbIQ index carrying a formally authorised EU Article 14 health claim rather than a literature-derived claim-strength assessment, and formulators working in EU-regulated markets should reference the exact authorised wording rather than paraphrasing it. Claim strength: High.

Fungal beta-glucans, structurally distinct from the cereal form (1,3/1,6-linkage vs. 1,3/1,4-linkage), are supported by a separate and more immune-focused evidence base. A randomized, double-blinded, placebo-controlled clinical trial in healthy adult volunteers evaluating Ganoderma lucidum (reishi)-derived β-1,3;1,6-D-glucan over 84 days found significant enhancement of CD3+, CD4+, and CD8+ T-lymphocyte populations and an improved CD4/CD8 ratio compared to placebo (Foods 2023), consistent with the class's proposed mechanism of engaging pattern-recognition receptors on innate immune cells, principally dectin-1, complement receptor 3, and toll-like receptors, which subsequently orchestrate downstream immune signalling. Claim strength: Moderate.

A broader review of fungal beta-glucan's health-promoting potential situates this immune-modulatory activity within a wider mechanistic and applied context, including proposed anti-carcinogenic, anti-pathogenic, and vaccine-adjuvant applications under active investigation, while noting that the strength of clinical evidence varies considerably by specific fungal source, extraction method, and molecular weight/branching pattern of the resulting glucan, none of which is fully standardized across the commercial supplement industry (PMC 2021). This structural heterogeneity is the primary reason immune-modulation claim strength for fungal beta-glucans is rated more conservatively than the regulatory-anchored cereal beta-glucan cholesterol claim. Claim strength: Moderate.

Maitake-derived beta-glucan specifically has additional preclinical and limited clinical interest around glycaemic and metabolic support, distinct from its immune-modulatory profile, though this application remains considerably less substantiated than either the reishi immune data above or the oat cholesterol claim, and should be labelled at correspondingly lower claim strength pending further human trial data specific to maitake fractions. Claim strength: Emerging.

A key formulation distinction across this entire compound class: fungal and cereal beta-glucans are not interchangeable despite sharing the "beta-glucan" name, owing to differing glycosidic linkage patterns, molecular weight, and degree of branching, all of which affect receptor engagement and physiological activity. A product formulated for cholesterol management should specify cereal (oat/barley) source material to align with the regulatory claim basis, while a product formulated for immune support should specify fungal source material to align with the relevant clinical literature. Claim strength: Moderate.

---

Dosage & Formulator Specification

Herbuno carries maitake-derived beta-glucan standardized to 30% by the Megazyme enzymatic-gravimetric method (the industry-standard assay for this compound class), alongside whole reishi fruiting-body extract and dehydrated reishi mushroom slices for lower-standardization formulation needs. Buyers formulating specifically for the EU/EFSA cholesterol claim should source cereal (oat) beta-glucan rather than the fungal material carried here, as the regulatory claim applies specifically to the 1,3/1,4-linked cereal form.

Clinical dosing for the oat beta-glucan cholesterol claim is explicit and regulatory-defined: a minimum of 3 g/day of oat beta-glucan is required to bear the EFSA-authorised claim, delivered from a food or supplement providing at least 1 g per quantified portion. Fungal beta-glucan immune-modulation trials have used more variable dosing, with the Ganoderma RCT cited above using a manufactured extract of approximately 75% beta-glucan purity administered daily for 84 days; formulators should reference the specific extract's assayed purity when translating trial protocols into finished-product serving sizes.

Analytical verification should specify the Megazyme (or equivalent enzymatic-gravimetric) total beta-glucan assay result and, where the product's positioning depends on it, confirmation of glycosidic linkage pattern and approximate molecular weight, since these structural parameters — not just the headline percentage — determine which mechanism of action (cholesterol-binding in the gut lumen for cereal beta-glucan vs. immune-receptor engagement for fungal beta-glucan) is actually relevant to a given extract.

Beta-glucans from both fungal and cereal sources are generally well tolerated, with gastrointestinal effects (bloating, gas) being the most commonly reported issue at higher doses, particularly with cereal beta-glucan's viscous gel-forming property in the gut. No major systemic safety signal has been established at typical dietary-supplement or clinical-trial dose ranges for either source, though immune-modulating fungal beta-glucans warrant standard formulator caution language regarding use alongside immunosuppressive medication given the mechanism's direct engagement of innate immune signalling.

---

Frequently Asked Questions — Beta-Glucans

Are oat beta-glucan and mushroom beta-glucan the same compound?
No. Both are polysaccharides built from beta-linked glucose units, but oat (cereal) beta-glucan has a 1,3/1,4 linkage pattern while mushroom (fungal) beta-glucan has a 1,3/1,6 pattern. This structural difference means they engage different physiological mechanisms and are not interchangeable for formulation purposes despite the shared name.

Is the oat beta-glucan cholesterol claim officially recognised, or just supported by studies?
It is a formally authorised health claim. The European Food Safety Authority reviewed 22 references, including three meta-analyses and 19 randomized controlled trials, and approved the specific claim wording "Oat beta-glucan has been shown to lower/reduce blood cholesterol" for products delivering at least 3 g/day, making it one of the most regulatory-substantiated claims in the botanical ingredient space.

How does mushroom-derived beta-glucan affect the immune system?
Fungal beta-glucans are recognised by pattern-recognition receptors on innate immune cells, principally dectin-1, complement receptor 3, and toll-like receptors. This receptor engagement triggers downstream immune signalling; a human randomized controlled trial found reishi-derived beta-glucan increased several T-lymphocyte populations over 84 days of daily use.

Why do beta-glucan extracts from different mushrooms vary in effectiveness?
Molecular weight, degree of branching, and extraction method all affect how well a given fungal beta-glucan engages immune receptors, and these parameters are not fully standardized across commercial sources. This is why buyers should confirm both the total beta-glucan percentage and, where possible, structural characterization rather than relying on the headline percentage alone.

Related compounds: Oat Beta-Glucan, Lentinan, Fucoidan, Astragalosides

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery